Next Phase Newsletter

A venture capital firm based in the East Coast has assets under management of about $135M and is investing from its third fund of outside capital, which closed in 2012. The firm invests in technology-enhanced services, and about 80% of the firm’s investments are in digital health technologies. Investments are in the form of equity or (less frequently) convertible debt, and the firm typically invests $500,000-$1.5 M. The firm invests in about 3-4 companies per year, and investments are typically made in Series A rounds. The firm primarily invests in the Northeast and Mid-Atlantic, but will consider investments outside those regions.

The firm invests broadly in the healthcare IT and analytics space, with past investments including a diagnostic platform, consumer wellness apps and health-focused media. They look for companies which provide software and data services to providers, payers, biopharmaceutical firms, and patients. The firm will consider investments related to any indication, but does not consider medical devices or therapeutic drugs. The firm invest only in companies that have fully developed a product.

The firm prefers to invest in companies that have existing revenues, but may consider pre-revenue companies with other strong evidence of their product’s market momentum such as adoption by free users. They like to see recurring revenue, high gross margins, and well-understood customer economics. The firm invests only in privately held companies, but has no other set requirements for management.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in California firm invests globally across industries from two active funds, one that is investing primarily in Series A and B rounds, and the other fund is investing in growth stage opportunities. The firm is usually an active lead investor, but may also invest as part of broader syndicates. Typical Series A investments are $5-10M up front with additional capital reserved. The firm supports portfolio companies through entrepreneurial experience, network, and recruiting.

The firm has a strategic focus in life sciences and digital health. Special interest areas include therapeutics (especially platform technologies), digital health (especially products that improve health outcomes), and novel applications of transformative technologies (such as genomics and synthetic biology).

The firm believes passionately that their role is to support and serve great management teams and entrepreneurs.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A USA based family office invests in primarily early-stage (seed, Series A, Series B) companies with truly innovative technologies with a typical investment size of $2-10M per company. The firm will generally lead investments, and invests globally with no geographic preference.

The firm is agnostic across life science sectors, including therapeutics, devices, and tools, but will not consider Healthcare IT or digital health technologies. The firm focuses on early stage preclinical to clinical-stage technology, though may be open to commercial-stage technology depending on the opportunity.

The firm is seeking companies with founders who have big ambitions, and a demonstrated ability to sell their team, investors, and partners on their vision. Previous startup experience is a big plus, but not required, and they will invest in young and first-time entrepreneurs.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A strategic fund of a large biopharmaceutical group focuses its investment strategy on oncology and infectious diseases. The fund has $150M under management and invests in the range of $1M – $10M per company. The Fund typically seeks to participate in Series A/B rounds, and is currently seeking 1-3 new equity investment opportunities a year. The fund also supports the in-licensing activities of the parent company in the EU and U.S.

The fund is mainly seeking digital health and healthcare IT investment opportunities at pre-commercial or commercial stage that will either improve drug development (e.g. patient recruitment, best responders, combination therapy) or that will impact the patient journey (e.g. patient monitoring, digital therapeutics, clinical decision support systems). In addition the firm considers therapeutic and diagnostic proposals that relate to oncology and infectious diseases. The fund is also seeking oncology and infectious disease therapeutics to in-license. The Fund is agnostic in terms of stage of development.

The fund is very active and supportive with their portfolio companies. The Fund typically seeks a board seat, and at times, also an observer seat. The Fund is looking for management teams experienced in the domain of interest and with entrepreneurial experience.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital fund backed by a family-office makes seed and early-stage equity investments; typical seed investments are of $250,000-500,000 initially with the potential for follow-on financing of up to $3 million of total exposure in any single opportunity. The firm is open to opportunities worldwide but has a preference for domestic investment; the fund currently has portfolio companies in North America, Europe and Oceania.

The first area of focus is Alzheimer’s Disease, where therapeutics (primary), diagnostics (secondary) and other solutions (tertiary) are all valid for consideration. The second area of investment is in technologies that enhance, accelerate, or reduce the cost of clinical trials and basic research, on the broadest scale, beyond Alzheimer’s Disease. This may include hardware and software tools, data analytics or aggregators, or novel approaches to current standards and protocols.

The firm seeks to make early-stage investments, but will also consider later-stage opportunities. The firm’s prior investments include drug discovery for the treatment of Alzheimer’s Disease, a diagnostic to track and recruit patients in early cognitive decline, a tablet-enabled benchtop microscope, an automated imaging tool for micro-dissection of tissue samples, and a platform looking to reinvent the model for pre-human drug testing and development. The fund also has a global partnership to develop intellectual property into potential compound candidates to treat Alzheimer’s Disease.

The firm strongly prefers to invest in privately held companies and will only back top scientists with defendable research, pursuing breakthrough approaches rather than traditional. In their Alzheimer’s portfolio, the fund looks to identify early-stage therapies that have received, and exhausted, non-dilutive sources of funding, such as grants from leading organizations; these companies will ideally be on the radar of large pharma counterparts but looking to obtain additional funds to collect the data required to form pharmaceutical partnerships. In the medical technology sector, the firm prefers to invest in companies developing platform technologies that can demonstrate and defend a clear value proposition addressing the ability to make clinical trials more efficient.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A global biotech headquartered in Europe with multiple R&D facilities across the USA and Western Europe has several marketed products in oncology, rare diseases, and neurosciences and has global commercial and development capabilities. The Company is actively seeking to expand its pipeline by working with early stage biotechs and academic groups. The Company is open to a variety of deal structures and seeks to construct deals that maximize the potential of the therapeutic program by leveraging the capabilities of all partners involved while meeting the needs of the entrepreneur/startup. The Company is also an anchor investor in a newly launched venture fund that will have an associated accelerator which will start / fund project focused companies to work in close partnership with their R&D team. This fund will add additional flexibility in the Company’s ability to work with the early stage biotech and academic communities.

The Company is focused on enhancing its pipeline with oncology, rare disease, and select neuroscience drug assets. The Company is interested in highly differentiated late stage pre-clinical and clinical stage therapeutic candidates with strong scientific rationale targeting indications with significant unmet medical need.

The Company has no strict requirements for companies or management teams and looks to work creatively and collaboratively on partnerships with early-stage companies. The Company is open to opportunities/companies on a global basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm with offices in the Bay Area and Western Europe manages over $230m investing in Life Sciences companies with a stage agnostic strategy. The initial investment size ranges from $0.5 million for seed stage companies to $5 million for later stages ventures, and reserves significant capital for follow on investments. The fund invests in Europe, US and Israel.

The firm is currently looking for new investment opportunities in therapeutics, medical devices, diagnostics and digital health with a focus on cardiovascular, oncology and neurology although they are opportunistic in other areas.

The firm seeks to invest in both private and public companies based in Europe, US and Israel.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.